Stuttgart - Delayed Quote EUR

Krystal Biotech, Inc. (4KB.SG)

Compare
152.15
+2.00
+(1.33%)
At close: January 31 at 9:34:10 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
241,519.00
50,699.00
--
--
--
Cost of Revenue
17,983.00
3,094.00
--
--
--
Gross Profit
223,536.00
47,605.00
--
--
--
Operating Expense
158,582.00
144,832.00
120,196.00
68,275.00
32,999.00
Operating Income
64,954.00
-97,227.00
-120,196.00
-68,275.00
-32,999.00
Net Non Operating Interest Income Expense
29,949.00
22,624.00
5,221.00
-1,295.00
832.00
Other Income Expense
-37,500.00
87,500.00
-25,000.00
--
--
Pretax Income
57,403.00
12,897.00
-139,975.00
-69,570.00
-32,167.00
Tax Provision
5,031.00
1,965.00
--
--
--
Net Income Common Stockholders
52,372.00
10,932.00
-139,975.00
-69,570.00
-32,167.00
Diluted NI Available to Com Stockholders
52,372.00
10,932.00
-139,975.00
-69,570.00
-32,167.00
Basic EPS
1.85
0.40
-5.49
-3.13
-1.71
Diluted EPS
1.78
0.39
-5.49
-3.13
-1.71
Basic Average Shares
28,447.94
27,154.19
25,491.72
22,196.85
18,787.16
Diluted Average Shares
29,464.81
27,751.81
25,491.72
22,196.85
18,787.16
Total Operating Income as Reported
27,454.00
-109,727.00
-145,196.00
-68,275.00
-32,999.00
Total Expenses
176,565.00
147,926.00
120,196.00
68,275.00
32,999.00
Net Income from Continuing & Discontinued Operation
52,372.00
10,932.00
-139,975.00
-69,570.00
-32,167.00
Normalized Income
86,585.37
-63,236.41
-114,975.00
-69,570.00
-32,167.00
Interest Income
--
22,624.00
5,221.00
197.00
832.00
Interest Expense
--
--
--
1,492.00
--
Net Interest Income
29,949.00
22,624.00
5,221.00
-1,295.00
832.00
EBIT
175,078.00
12,897.00
-139,975.00
-68,078.00
-32,167.00
EBITDA
181,090.00
17,904.00
-137,332.00
-66,229.00
-30,316.00
Reconciled Cost of Revenue
17,983.00
3,094.00
--
--
--
Reconciled Depreciation
6,012.00
5,007.00
2,643.00
1,849.00
1,851.00
Net Income from Continuing Operation Net Minority Interest
52,372.00
10,932.00
-139,975.00
-69,570.00
-32,167.00
Total Unusual Items Excluding Goodwill
-37,500.00
87,500.00
-25,000.00
--
--
Total Unusual Items
-37,500.00
87,500.00
-25,000.00
--
--
Normalized EBITDA
218,590.00
-69,596.00
-112,332.00
-66,229.00
-30,316.00
Tax Rate for Calcs
0.00
0.00
--
--
--
Tax Effect of Unusual Items
-3,286.63
13,331.59
--
--
--
12/31/2020 - 11/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

NBTX Nanobiotix S.A.
3.4850
-1.83%
 
NXTC NextCure, Inc.
0.8048
+0.73%
 
XNCR Xencor, Inc.
18.28
-1.19%
 
BCAX Bicara Therapeutics Inc.
12.62
-2.25%
 
SANN.SW Santhera Pharmaceuticals Holding AG
17.12
+4.39%
 
BCYC Bicycle Therapeutics plc
13.39
+4.86%
 
XLO Xilio Therapeutics, Inc.
0.7050
+1.45%
 
ZBIO Zenas BioPharma, Inc.
8.02
+5.25%
 
TSVT 2seventy bio, Inc.
2.6600
+1.53%
 
IDYA IDEAYA Biosciences, Inc.
24.35
+1.97%